ProfileGDS5678 / 1438294_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 75% 75% 75% 75% 71% 76% 75% 75% 75% 77% 77% 76% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0278376
GSM967853U87-EV human glioblastoma xenograft - Control 25.02575
GSM967854U87-EV human glioblastoma xenograft - Control 35.0283875
GSM967855U87-EV human glioblastoma xenograft - Control 45.0598375
GSM967856U87-EV human glioblastoma xenograft - Control 54.9792675
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4711771
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.0221176
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9812575
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0152375
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0218175
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1892177
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.214577
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.027476
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.1303476